- Investigator
- Daniel E Soffer
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
Treats Adults
Daniel E Soffer, MD
Cardiologist, Interventional Cardiologist
Daniel E Soffer, MD
(904) 383-1011
Request appointment online
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 14 publications
- Clopidogrel , 11 publications
- Ticagrelor , 10 publications
- Platelet Aggregation , 8 publications
Research activity
Active clinical trials
My publications
Filter publications
37 publications
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation
鈥�2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science
鈥�2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association
鈥�2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis
鈥�2019
Pharmacodynamic Effects of Vorapaxar聽in Patients聽With and Without聽Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science
鈥�